Please note: This study was sponsored by Edwards Lifesciences. Dr. Barker has served on
advisory boards for Medtronic and Boston Scientific; and has been a consultant to Edwards …

OBJECTIVES The feasibility of an Amplatzer septal occluder closure of ventricular septal
defects (VSDs) under echocardiographic guidance has already been proven. However, the …

Objectives This study evaluated the feasibility, effectiveness, and safety of a biodegradable
(BD) occluder for closure of ventricular septal defect (VSD) in an acute canine model …

Degradable heart occluders are a promising replacement for currently clinically used non-
degradable ones without concerns about the complications caused by the persistent residue …

BACKGROUND Transcatheter device closure of ventricular septal defect (VSD) has become
an attractive alternative to surgery. We report here on our early experiences of transcatheter …

Transcatheter closure of atrial septal defect and patent foramen ovale with Carag
bioresorbable septal occluder: first-in-man experience with 24-month follow-up - PMC Back …

The Lifetech Multifunctional occluder is a versatile device with an improved delivery and
flexibility that reduces the risk of atrioventricular block. This is a retrospective, descriptive …

Transcatheter closure of cardiac defects has been possible for nearly 2 decades. Several
different devices have been used to close a variety of cardiac defects. im4 A clamshell …

Although the use of bioabsorbable occluder is expected to reduce the risk of metal occluder-
related complications, it has not been approved due to incomplete degradation and new …

Transcatheter closure of ventricular septal defects is considered first-line therapy when
anatomically appropriate but is often challenged by proximity to the conduction system in …